IE62568B1 - Use of acetyl d-carnitine in the therapeutic treatment of glaucoma - Google Patents

Use of acetyl d-carnitine in the therapeutic treatment of glaucoma

Info

Publication number: IE62568B1
Authority: IE; Ireland
Prior art keywords: carnitine; acetyl; glaucoma; pharmacologically acceptable; treatment
Prior art date: 1988-12-01

Application number

IE384089A

Other languages

English (en)

Other versions

IE893840L (en

Inventor

Claudio Cavazza

Original Assignee

Sigma Tau Ind Farmaceuti

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-12-01

Filing date

1989-11-30

Publication date

1995-02-08

1989-11-30 Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti

1990-06-01 Publication of IE893840L publication Critical patent/IE893840L/xx

1995-02-08 Publication of IE62568B1 publication Critical patent/IE62568B1/en

Links

RDHQFKQIGNGIED-QMMMGPOBSA-N O-acetyl-D-carnitine Chemical compound CC(=O)O[C@@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-QMMMGPOBSA-N 0.000 title claims abstract description 19
238000011282 treatment Methods 0.000 title claims abstract description 16
230000001225 therapeutic effect Effects 0.000 title claims abstract description 14
208000010412 Glaucoma Diseases 0.000 title claims abstract description 13
150000003839 salts Chemical class 0.000 claims abstract description 12
239000000203 mixture Substances 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
239000004480 active ingredient Substances 0.000 claims 2
239000002552 dosage form Substances 0.000 claims 1
239000007788 liquid Substances 0.000 claims 1
239000003814 drug Substances 0.000 abstract description 3
210000001508 eye Anatomy 0.000 description 9
PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 8
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
208000024827 Alzheimer disease Diseases 0.000 description 3
201000002862 Angle-Closure Glaucoma Diseases 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
229960001009 acetylcarnitine Drugs 0.000 description 3
239000008103 glucose Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
PHIQHXFUZVPYII-LURJTMIESA-N (S)-carnitine Chemical compound C[N+](C)(C)C[C@@H](O)CC([O-])=O PHIQHXFUZVPYII-LURJTMIESA-N 0.000 description 2
FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
108010066477 Carnitine O-acetyltransferase Proteins 0.000 description 2
102100036357 Carnitine O-acetyltransferase Human genes 0.000 description 2
108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 2
102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 2
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
206010030043 Ocular hypertension Diseases 0.000 description 2
229960004203 carnitine Drugs 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
229960004544 cortisone Drugs 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
GJTJQSPLLQWKMB-BKZSKYJJSA-N (3R)-5-deuterio-3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]pentanoate Chemical compound C(C[2H])(=O)[C@](O)(C[N+](C)(C)C)CC([O-])=O GJTJQSPLLQWKMB-BKZSKYJJSA-N 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
206010011703 Cyanosis Diseases 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
240000007711 Peperomia pellucida Species 0.000 description 1
208000018262 Peripheral vascular disease Diseases 0.000 description 1
206010036631 Presenile dementia Diseases 0.000 description 1
208000003782 Raynaud disease Diseases 0.000 description 1
208000012322 Raynaud phenomenon Diseases 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
229960002537 betamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000005252 bulbus oculi Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
201000005682 chronic closed-angle glaucoma Diseases 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
229940061607 dibasic sodium phosphate Drugs 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
229960004756 ethanol Drugs 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000004410 intraocular pressure Effects 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229940111688 monobasic potassium phosphate Drugs 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
229960002668 sodium chloride Drugs 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
238000002627 tracheal intubation Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

IE384089A 1988-12-01 1989-11-30 Use of acetyl d-carnitine in the therapeutic treatment of glaucoma IE62568B1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT8848614A IT1224795B (it)	1988-12-01	1988-12-01	Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento

Publications (2)

Publication Number	Publication Date
IE893840L IE893840L (en)	1990-06-01
IE62568B1 true IE62568B1 (en)	1995-02-08

Family

ID=11267644

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IE384089A IE62568B1 (en)	1988-12-01	1989-11-30	Use of acetyl d-carnitine in the therapeutic treatment of glaucoma

Country Status (13)

Country	Link
US (2)	US5145871A (da)
EP (1)	EP0446268B1 (da)
JP (1)	JP2763400B2 (da)
KR (1)	KR950004885B1 (da)
AU (1)	AU628116B2 (da)
CA (1)	CA2004239C (da)
DK (1)	DK175891B1 (da)
ES (1)	ES2040106T3 (da)
GR (1)	GR1000465B (da)
IE (1)	IE62568B1 (da)
IT (1)	IT1224795B (da)
WO (1)	WO1990006111A1 (da)
ZA (1)	ZA899176B (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1254314B (it) *	1992-03-27	1995-09-14	Sigma Tau Ind Farmaceuti	Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
IT1263004B (it) *	1992-10-08	1996-07-23	Sigma Tau Ind Farmaceuti	Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
US5629345A (en) *	1993-07-23	1997-05-13	Vide Pharmaceuticals	Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
US5965620A (en) *	1993-07-23	1999-10-12	Vide Pharmaceuticals	Methods and compositions for ATP-sensitive K+ channel inhibition for lowering intraocular pressure
IT1276225B1 (it) *	1995-10-17	1997-10-27	Sigma Tau Ind Farmaceuti	Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
IT1276253B1 (it)	1995-12-15	1997-10-27	Sigma Tau Ind Farmaceuti	Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
IT1291113B1 (it) *	1997-03-20	1998-12-29	Sigma Tau Ind Farmaceuti	Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US6090848A (en) *	1997-12-01	2000-07-18	Sigma-Tau Healthscience S.P.A.	Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
US5863940A (en)	1997-12-01	1999-01-26	Sigma-Tau Healthscience S.P.A.	Medicament and therapeutical method for treating idiopathic asthenozoospermia
DK0951909T4 (da)	1998-03-19	2011-01-24	Sigma Tau Ind Farmaceuti	Kombinationspræparat omfattende en L-carnitin eller en alkanoyl-L-carnitin, en glycosaminoglycan og/eller bestanddel deraf
US6573299B1 (en)	1999-09-20	2003-06-03	Advanced Medical Instruments	Method and compositions for treatment of the aging eye
EP1267903A4 (en) *	2000-02-08	2003-08-06	Pharmacia Corp	METHOD FOR TREATING GLAUCOMA
HUP0401145A3 (en) *	2001-07-06	2008-08-28	Ciba Sc Holding Ag	Process for the preparation of intermediates useful in the synthesis of statin derivatives especially 7-amino 3,5-dihydroxy heptanoic acid derivatives, and intermediates thereof
KR100996226B1 (ko) *	2001-10-31	2010-11-24	유니버시티 오브 노스 텍사스 헬스 사이언스 센터	뼈 형태발생 단백질(ｂｍｐ), ｂｍｐ 수용체 및 ｂｍｐ결합 단백질 및 녹내장 진단 및 치료에서 그의 용도
ITRM20020492A1 (it) *	2002-10-01	2004-04-02	Sigma Tau Ind Farmaceuti	Uso della propionil l-carnitina per la preparazione di un medicamento per il trattamento del glaucoma.
CN1964630A (zh)	2003-02-13	2007-05-16	耶希瓦大学艾伯塔·爱恩斯坦医学院	通过控制下丘脑的长链脂肪酰基－辅酶A(LC－CoA)的水平来调控食物摄取和葡萄糖产生
US8802139B2 (en)	2003-06-26	2014-08-12	Intellipharmaceutics Corp.	Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US6951658B1 (en)	2003-07-08	2005-10-04	Pearson Research & Development Limited	Emu-based compositions for mental well-being and method of use
US7718697B2 (en) *	2003-12-17	2010-05-18	Alcon, Inc.	Method for treating glaucoma comprising administering α-lipoic acid
US20050232911A1 (en) *	2004-04-19	2005-10-20	Schreiber Brian D	Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US8569367B2 (en) *	2004-11-16	2013-10-29	Allergan, Inc.	Ophthalmic compositions and methods for treating eyes
US8168206B1 (en)	2005-10-06	2012-05-01	Allergan, Inc.	Animal protein-free pharmaceutical compositions
US7282225B1 (en)	2006-09-27	2007-10-16	Occular Technologies, Inc.	Composition and methods for improving retinal health
EP2363126A1 (en)	2010-03-04	2011-09-07	SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.	Composition comprising as active ingredient L-carnitine in combination with hydroxykynurenine-O-beta-DL-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation
EP2642991A1 (en)	2010-11-22	2013-10-02	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Therapeutical method for the treatment of the leber optic
US8957048B2 (en)	2011-10-06	2015-02-17	Allergan, Inc.	Compositions for the treatment of dry eye
US9907826B2 (en)	2011-12-07	2018-03-06	Allergan, Inc.	Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
ES2797650T3 (es)	2011-12-07	2020-12-03	Allergan Inc	Administración de lípido eficiente a película lagrimal humana usando un sistema de emulsión sensible a sal
EP2783695A1 (en)	2013-03-28	2014-10-01	SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.	Physiological supplement or medicament for ophthalmic use containing L-carnitine or alkanoyl L-carnitines in combination with eledoisin
JP6768653B2 (ja)	2014-11-25	2020-10-14	アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ	安定したオメガ−３眼科用組成物
IT201900002913A1 (it)	2019-03-01	2020-09-01	Nicola Pescosolido	Composto utile per il trattamento del glaucoma
IT202100020729A1 (it)	2021-08-02	2023-02-02	Univ Degli Studi Di Napoli Federico Ii	Preparazione combinata per il trattamento della malattia di Pompe

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1262864A (en) *	1982-09-17	1989-11-14	Clarence D. Cone	Method for producing oncolysis

1988
- 1988-12-01 IT IT8848614A patent/IT1224795B/it active
1989
- 1989-11-27 AU AU46584/89A patent/AU628116B2/en not_active Expired
- 1989-11-27 EP EP90900320A patent/EP0446268B1/en not_active Expired - Lifetime
- 1989-11-27 JP JP2502051A patent/JP2763400B2/ja not_active Expired - Lifetime
- 1989-11-27 KR KR1019900701559A patent/KR950004885B1/ko not_active Expired - Lifetime
- 1989-11-27 WO PCT/IT1989/000076 patent/WO1990006111A1/en not_active Ceased
- 1989-11-27 ES ES199090900320T patent/ES2040106T3/es not_active Expired - Lifetime
- 1989-11-28 US US07/442,702 patent/US5145871A/en not_active Expired - Lifetime
- 1989-11-30 ZA ZA899176A patent/ZA899176B/xx unknown
- 1989-11-30 CA CA002004239A patent/CA2004239C/en not_active Expired - Lifetime
- 1989-11-30 IE IE384089A patent/IE62568B1/en not_active IP Right Cessation
- 1989-12-01 GR GR890100797A patent/GR1000465B/el not_active IP Right Cessation
1991
- 1991-04-23 US US07/689,527 patent/US5432199A/en not_active Expired - Lifetime
- 1991-05-21 DK DK199100950A patent/DK175891B1/da not_active IP Right Cessation

Also Published As

Publication number	Publication date
DK95091A (da)	1991-05-21
US5432199A (en)	1995-07-11
KR920702216A (ko)	1992-09-03
IT8848614A0 (it)	1988-12-01
CA2004239C (en)	1999-11-09
WO1990006111A1 (en)	1990-06-14
US5145871A (en)	1992-09-08
AU628116B2 (en)	1992-09-10
IE893840L (en)	1990-06-01
CA2004239A1 (en)	1990-06-01
GR1000465B (el)	1992-07-30
JP2763400B2 (ja)	1998-06-11
DK175891B1 (da)	2005-05-30
EP0446268A1 (en)	1991-09-18
KR950004885B1 (ko)	1995-05-15
GR890100797A (en)	1991-03-15
JPH04502161A (ja)	1992-04-16
IT1224795B (it)	1990-10-24
DK95091D0 (da)	1991-05-21
EP0446268B1 (en)	1993-04-14
AU4658489A (en)	1990-06-26
ES2040106T3 (es)	1993-10-01
ZA899176B (en)	1990-09-26

Legal Events

Date	Code	Title	Description
2009-12-23	MK9A	Patent expired

Publication	Publication Date	Title
EP0446268B1 (en)	1993-04-14	Use of acetyl d-carnitine in the therapeutic treatment of glaucoma
EP0093380B1 (en)	1987-01-14	Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
CA1325382C (en)	1993-12-21	Locally administrable therapeutic composition for inflammatory disease
US5037851A (en)	1991-08-06	Use of acetyl l-carnitine in the therapeutic treatment of cataract, and pharmaceutical compositions useful in such treatment
US5488069A (en)	1996-01-30	Ophthalmic pharmaceutical composition containing N-acetyl-cysteine and polyvinylalcohol
US5510381A (en)	1996-04-23	Method of treatment of mania and bipolar disorder
US5270050A (en)	1993-12-14	Paracetamol-based pharmaceutical composition
US4464393A (en)	1984-08-07	Use of alkanoyl L-carnitines in the therapeutical treatment of myopathies and muscular dystrophies
KR19980063712A (ko)	1998-10-07	망막증의 치료에 유용한 저급 알카노일 ｌ-카르니틴
US5041450A (en)	1991-08-20	Treatment of ocular inflammation
DE68906028T2 (de)	1993-07-22	Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
US4923877A (en)	1990-05-08	Composition and method for treating glaucoma
Pederson et al.	1982	Medical therapy for experimental hypotony
JPH1029938A (ja)	1998-02-03	虚血性眼疾患の予防および／または治療剤
RU2051651C1 (ru)	1996-01-10	Основа для глазных капель
JPH05505605A (ja)	1993-08-19	眼圧低下剤としての５―トランスプロスタグランジンＦ↓２αの使用
Leopold	1968	Trends in Ocular Therapy: The 23rd Sanford S. Gifford Memorial Lecture
JPH08310955A (ja)	1996-11-26	網膜疾患治療剤
CA2015427A1 (en)	1990-10-26	Pharmaceutical composition for topical ophthalmic use having improved local tolerability
CA2447883A1 (en)	2002-11-28	Use of nf-kappa-b inhibitors to treat dry eye disorders
JP2741285B2 (ja)	1998-04-15	緑内障治療剤
AU2002309963A1 (en)	2003-05-08	Use of NF-KAPPA-B inhibitors to treat dry eye disorders
MXPA97007269A (en)	1998-07-03	A method of treatment of mania and disorderbipo